期刊文献+

替米沙坦血药浓度高效液相—荧光检测方法的研究

Research on Telmisartan Concentration in Human Plasma by HPLC-FLU
暂未订购
导出
摘要 目的建立测定血浆中替米沙坦浓度的高效液相—荧光色谱分析方法。方法血浆样品以乙醚为提取溶剂处理,分析柱为KromsailKR100-5C18色谱柱(5μm,150 mm×4.6 mm)。流动相为0.01 mol/L KH2PO4水溶液(pH3.5):乙腈=54:46(V/V),激发波长Ex=305nm,发射波长Em=365 nm,流速1.0 ml/min,柱温为室温,进样量20μl。结果替米沙坦在5.0~500 ng/ml范围内线性良好(r=0.999 8),最低检测浓度为2.5 ng/ml(S/N〉3)。该方法的相对回收率为(100.7±4.2)%(n=5),绝对回收率为(88.4±3.9)%(n=5),日内RSD为(3.1±1.0)%(n=5),日间RSD为(4.0±1.5)%(n=5)。结论本方法准确、灵敏、特异性强、重显性好,适用于血浆中替米沙坦浓度测定和体内药代动力学研究。 Objective To establish a HPLC-FLU method for the determination of telmisartan concentration in human plasma.Methods The plasma examples were extracted with ethoxyethane.The separation was performed on Kromsail KR100-5C18(5μm,150 mm×4.6 mm)at room temperature with mobile phase consisted of 0.01 mol·L-1 KH2PO4 water solution(pH 3.5);cyanomethane=54:46(V/V).The λEx was set at 305nm and the λEm was at 365nm,and the sample size was 20μl.Results The linear range of telmisartan was 5.0500ng·ml-1(r=0.999 8),with the lowest detectable limit at 2.5ng·ml-1(S/N〉3).The relative recovery rate was(100.7±4.2)%(n=5)and the absolute was(88.4±3.9)%(n=5).The intra-day RSD was(3.1±1.0)%(n=5)and the inter-day was(4.0±1.5)%(n=5).Conclusion The method is simple,sensitive,accurate and reproducible,and suitable for the determination and pharmacokinetic study of telmisartan in human plasma.
出处 《临床军医杂志》 CAS 2009年第4期706-707,共2页 Clinical Journal of Medical Officers
关键词 替米沙坦 高效液相—荧光色谱 人体血浆 telmisartan HPLC-FLU human plasma
  • 相关文献

参考文献5

二级参考文献18

  • 1Timmermans PB. Angiotensin Ⅱ receptor antagonists: an emerging new class of cardiovascular therapeutics[J]. Hypertens Res, 1999,22(2): 147-53.
  • 2Monton M, Jimenez A, Nunez A et al. Comparative effects of angiotensin Ⅱ AT-1-type receptor antagonists in vitro on human platelet activation[J]. J Cardiovasc Pharmacol, 2000,35(6): 906-13.
  • 3Li J, Hirose N, Kawamura M et al. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin Ⅱ receptor antagonist (valsartan) in the cholesterol-fed rabbits[J]. Atherosclerosis, 1999,143(2): 315-26.
  • 4Stangier J, Schmid J, Turck D et al. Absorption, Metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers[J]. J Clin Pharmacol, 2000,40(12pt1):1312-22.
  • 5Stangier J, Su CA, Roth W. pharmacokinetics of orally and intravenously administered telmisartan in healthy young and volunteers and in hypertensive patients[J]. J Int Med Res, 2000,28(4):149-67.
  • 6Israili ZH. Clinical pharmacokinetics of angiotensin Ⅱ (AT1) receptor blockers in hypertension[J]. J Hum Hypertens, 2000,14(Suppl 1):S73-6.
  • 7Oparil S. Newly emerging pharmacologic differences in angiotensin Ⅱ receptor blockers[J]. Am J Hypertens, 2000,13(1 Pt 2):18S-24S.
  • 8Hernandez-Hernandez R, Velasco M, Armas-Hernandez MJ et al. Angiotensin Ⅱ receptor antagonists in arterial hypertension[J]. J Hum Hypertens, 2000,14(Suppl 1): S69-75.
  • 9Mcllellan KJ, Markham A. Telmisartan[J]. Drugs, 1998,56(6):1039-46.
  • 10Van Heiningen PN, Van Lier JJ, de Bruin H et al. Single dose study on the pharmacodynamics and pharmacokinetics of the angiotensin Ⅱ antagonist BIBR02777SE[J]. Pharm World Sci, 1994,16(Suppl): 4-7.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部